Assist Professor: @thenosm / Uro Oncologist: @TBRHSF Former Clin Fellow @LavalUniversity Former Res.fellow: UniversitéParis
São Paulo
Joined August 2020
- Tweets305
- Following1.7K
- Followers503
- Likes1.7K
Caio Suartz retweeted
Just out in @JAMAOnc... a summary of my view on how we can do more for financially constrained health systems using dose optimization principles and common sense.
Invite folks to read and discuss, curious where you agree and where you’d push back 👇
jamanetwork.com/journals/jam…
Caio Suartz retweeted
Presented at #ESMO26:
In patients with muscle-invasive bladder cancer, event-free survival at 24 months was 63.5% with perioperative durvalumab plus neoadjuvant enfortumab vedotin as compared with 45.1% with surgery alone. Full phase 3 VOLGA trial results: nej.md/4z7dQFm
@myESMO
ALT A graph showing event-free survival for the durvalumab–enfortumab vedotin (EV) and control groups (intention-to-treat population).
Caio Suartz retweeted
Great discussions at @IBCG_BladderCA #IBCG26 tackling some of the most controversial topics affecting our decision-making at the point of care.
Bringing together global experts to debate the evidence, challenge current thinking, and build consensus where the data don’t always give us a clear answer.
@AndreaNecchi @mouwlab @LAUrology_NL @UroDocAsh @montypal @FaltasLab @siadaneshmand
Caio Suartz retweeted
Very pleased to announce Mario Fernandez as the inaugural LATAM Liaison on the IBCG Board.
Mario will help us broaden IBCG’s engagement across Latin America, strengthen regional relationships, and create new opportunities for collaboration, education, and scientific exchange.
Could not think of a better person to help lead this effort.
@UrogerliMD @pjhensley11 @AmirHorowitz @mouwlab @spsutkaMD @shilpaonc @AndreaNecchi @LAUrology_NL @karima_oualla @joanfundi @PGrivasMDPhD @marigfern @SpiessPhilippe @IBCG_BladderCA #IBCG26
Caio Suartz retweeted
Delighted to welcome Phil Spiess to the IBCG Board as our inaugural GSRGT Liaison.
This new role will help deepen collaboration between IBCG and the Global Society of Rare Genitourinary Tumors, with a focus on areas of shared scientific and strategic interest.
Looking forward to what we can build together. @GTumors @UrogerliMD @pjhensley11 @AmirHorowitz @mouwlab @spsutkaMD @shilpaonc @AndreaNecchi @LAUrology_NL @karima_oualla @PGrivasMDPhD @marigfern @SpiessPhilippe @IBCG_BladderCA #IBCG26
Caio Suartz retweeted
20 years ago, IBCG started with a small group around a table.
Later this month, friends and colleagues from around the world gather in Houston for #IBCG26. Two days around the table tackling some of the hardest questions in #BladderCancer, debating the evidence and challenging each other on where we go next.
Looking forward to seeing you all!
@UrogerliMD @spsutkaMD @LAUrology_NL @shilpaonc @mouwlab @pjhensley11 @AndreaNecchi @AmirHorowitz @PGrivasMDPhD @karima_oualla @SimaPorten @joanfundi @marigfern
Caio Suartz retweeted
New in @JAMANetworkOpen: @SWOG S1600, a multicenter phase 3 RCT, found no reduction in 30- or 90-day complications w/ specialized immunonutrition vs standard nutrition after cystectomy. Exploratory DFS/OS favored immunonutrition. #BladderCancer
@JhamiltonReeves @DrJoeUnger @JMHolzbeierlein @FoxChaseCancer @BCM_Urology @JanetKukreja @eugenekanglee @URMCUrology @DrDawnHershman @fischmd @lynnhenrymd jamanetwork.com/journals/jam…
Caio Suartz retweeted
Delighted to welcome Laura Mertens to the IBCG Scientific Advisory Board.
@LAUrology_NL has been a terrific contributor to our Editorial Board, and it has been wonderful to see her leadership continue to grow through key initiatives in the EAU region and globally.
Thrilled to have her voice, perspective, and energy helping guide IBCG’s work going forward.
@nki_nl @hetavl @IBCG_BladderCA @UrogerliMD @shilpaonc @AndreaNecchi @spsutkaMD @mouwlab @pjhensley11 @AmirHorowitz @karima_oualla @PGrivasMDPhD @SpiessPhilippe
Caio Suartz retweeted
Before the first overnight call, the first difficult catheter, we had dinner.
It was a pleasure welcoming our new Urology residents and spending an evening getting to know everyone. A big thank you to Dr. Walid Shahrour for hosting such a warm gathering.
Caio Suartz retweeted
Proud to chair the 5th annual IBCG Bladder Cancer Forum at #AUA26 alongside an extraordinary group of global colleagues, thought leaders, and patient advocates committed to advancing care for patients with bladder cancer.
What began five years ago as a vision for open, high-level, multidisciplinary dialogue has grown into one of the most engaging and collegial forums at the meeting. This year’s debates and discussions once again reflected the passion, expertise, and shared purpose of this community.
My sincere thanks to all of the speakers, moderators, panelists, advocates, and attendees who made the session such a success.
#AUA2026 @IBCG_BladderCA #BladderCancer @BladderCancerUS @WorldBladderCan
Caio Suartz retweeted
Proud moment for our Urology team at NOSM University following very positive feedback from the recent external review by the Royal College of Physicians and Surgeons of Canada.@thenosm @waleedshabana @ShahrourWalid @DrPianezza @CSuartz @dryasser_noor
🤖 Made with AI
Caio Suartz retweeted
For those of us who still do some laparotomies.
Small vs Large Bites for Abdominal Midline Incisions jamanetwork.com/journals/jam…
Caio Suartz retweeted
🧬 A recent systematic review evaluated the diagnostic, prognostic, and predictive value of plasma and urine #ctDNA in #UrothelialCarcinoma. Findings underscore ctDNA’s growing role as a promising biomarker for disease monitoring and treatment decision‑making: buff.ly/dgCPjtA
Caio Suartz retweeted
Pleased to share that the 2026 @NCCN Bladder Cancer Guidelines now incorporate the @IBCG_BladderCa risk stratification framework for intermediate-risk NMIBC.
A milestone reflecting more than a decade of collaborative work by colleagues worldwide
einpresswire.com/article/901…
@UrogerliMD @drtanws @shilpaonc @pjhensley11 @mouwlab @AndreaNecchi @LAUrology_NL @AmirHorowitz @karima_oualla @PGrivasMDPhD @paolo_gontero @pcvblack @MaxKates @SpiessPhilippe @RobertoContieri @KKBree @LauraBukavinaMD @MRoupret @joanfundi @UroToday @BladderCancerUS @WorldBladderCan
Caio Suartz retweeted
Very elegant and thoughtful discussion by @DrTylerStewart #ASCOGU2026
1. B-15: EV-P as the new SOC in MIBC, highlights Qs re: no. of cycles & future of bladder preservation
2. RC48G001: 2nd line DV in mUC- future role of DV in the fifteen landscape?
@tompowles1 @MattGalsky @Uromigos @OncoAlert @DrChoueiri @ERPlimackMD @apolo_andrea @brian_rini
Caio Suartz retweeted
New IBCG consensus:
Optimal Management of Muscle-invasive Bladder Cancer: Recommendations from the International Bladder Cancer Group
(IBCG)
Full text: authors.elsevier.com/a/1mf5C…
@shilpaonc @AndreaNecchi @UrogerliMD @PGrivasMDPhD @FaltasLab @pjhensley11 @siadaneshmand @niyatilobo @mouwlab @karima_oualla @UroMoschini @BogdanaSchmidt @AStenzl @JoshMeeks @DrRosenbergMSK #OncSurgery
Caio Suartz retweeted
Original Article: Perioperative Enfortumab Vedotin and Pembrolizumab in Bladder Cancer (phase 3 KEYNOTE-905/EV-303 trial) nej.md/4czl8sG
Editorial: Enfortumab Vedotin plus Pembrolizumab as Perioperative Therapy nej.md/4twnv5T
#Oncology
ALT The Kaplan–Meier estimates of event-free survival as assessed by blinded independent central review in the intention-to-treat population, which included all participants who had undergone randomization.
ALT The Kaplan–Meier estimates of overall survival in the intention-to-treat population
Caio Suartz retweeted
In cisplatin-ineligible patients with muscle-invasive bladder cancer, enfortumab vedotin–pembrolizumab plus surgery led to better event-free survival (74.7%, vs. 39.4%) and overall survival (79.7%, vs. 63.1%) than surgery alone at 2 years. Full phase 3 KEYNOTE-905/EV-303 trial results: nej.md/4czl8sG
Editorial: Enfortumab Vedotin plus Pembrolizumab as Perioperative Therapy nej.md/4twnv5T
ALT The Kaplan–Meier estimates of event-free survival as assessed by blinded independent central review in the intention-to-treat population, which included all participants who had undergone randomization.
Caio Suartz retweeted
JUST IN: EVP does it again! Positive EV-304 data (following @myESMO 2025 with EV-303 trial): EVP improves EFS and OS in in cisplatin-ELIGIBLE patients with muscle-invasive bladder cancer!
pfizer.com/news/press-releas… – at Boston, MA
